Hindu Americans oppose 'negative portrayal' of Hinduism by CNN

Brussels/Amsterdam, Apr 16: As the novel coronavirus continues to wreak havoc in the western world since its outbreak in Wuhan last December, researchers believe that the Chinese leadership is trying to absolve President Xi Jinping by using a section of the western media to influence public opinion globally.

"There are clear indications that China is conducting activities in a persistent and systematic manner to influence public opinion-making, academia, think tanks and political decision-making among the member states of the Belt and Road Initiative (BRI) in general and western capital cities in particular," Siegfried O Wolf, Director of Research at Brussels-based think tank South Asia Democratic Front, said.

Some western media say some Chinese officials were secretly aware that they were facing a pandemic from the new coronavirus but allowed Wuhan to host a mass banquet for tens of thousands of people and millions began their annual trip home for the Lunar New Year celebrations.

The pandemic has since then affected 210 countries and territories around the world. Over 2 million people have been declared positive in which over 134,000 lost their lives.

"The frequency and extra-ordinary large scale of Chinese sponsored events in European political hubs, like in Brussels, and the subsequent media coverage can be seen as evidence for Beijing's public diplomacy efforts. However, the rising skepticism within the EU regarding Xi Jinping's development projects and the emerging questioning of Chinese sources funding Free Universities, like the one in Berlin, shows that this strategy produced mixed results so far," Wolf said.

He added, "However, one must also state that these efforts helped China to gain certain leverage among many non-Chinese media, western as well as non-western ones. Today, we can observe that China's political leadership tries to instrumentalise this influence for a major image campaign to distract from the fact that it carries the initial responsibility for the dramatic spread of COVID-19 by holding back key information."

Wolf also said that the current internal dynamics in China, like the shirking of responsibilities by the local authorities, are most-likely part of a twofold strategy. Firstly, there is the strategic component - namely, to reaffirm to the general public that the Communist Party of China is still in full control of the situation. The second strategic pillar is one of 'whitewashing'.

"Concretely, Beijing's obvious aim is to distract the domestic and international attention from the real, but hidden causes of the Coronavirus outbreak and its potential reputational and political consequences for Xi Jinping and his BRI," he stated.

Yoana Barakova, a Research Analyst at European Foundation for South Asian Studies (EFSAS), an Amsterdam-based think-tank, said, "The death of Dr. Li Wenliang, one of the very few medical professionals who tried to warn the world in December 2019 about the looming threat, sparked widespread condemnation around the international community in early February. Yet, little did he know that his legacy would continue much later after his demise, with the emboldened Chinese government trying to cover up its missteps through hardcore censorship after being exposed for undermining and underestimating the initial danger."

The researchers believe that the deterioration in press freedom under Jinping's regime has become more evident in recent days, with local authorities trying to control the state narrative by cosmetically placing media's focus on government's superficial attempts to tackle the crisis.

Beijing, Mar 29: In a rare display of public anger in China, dozens of people in central Hubei province, the epicentre of the coronavirus outbreak till recently, attacked official vehicles after they were stopped from crossing a bridge and travel to neighbouring Jiangxi after the lifting of the lockdown.
Hubei province with over 56 million people was kept under lockdown from January 23 as part of aggressive measures to bring down COVID-19 cases which rapidly spread in the area.

Videos on Chinese social media on Friday showed unprecedented scenes of police from Hubei and Jiangxi clashing on the bridge connecting the two provinces over barricades erected from stopping Hubei people from moving out over fears of coronavirus spreading.

Policemen from both sides argued over how to verify if people were allowed to enter Jiangxi, according to local media reports.

It was a major relief for millions of people in Hubei province, when the Chinese government which kept it under lockdown lifted the restrictions on travel.

The government will permit people from the province to travel if they hold a green health code, meaning no contact with any infected or suspected COVID-19 cases.

But people of Hubei to their shock on Friday found roadblocks on the 1st Yangtze River Bridge that separates Huangmei county in Hubei erected by Huangmei county of Jiangxi province.

In local media reports, witnesses were quoted as saying that Huangmei police in Jiujiang erected roadblocks on the bridge to stop people from Hubei from crossing it, a move they alleged stigmatised them.

Video footage shared online showed rows of police armed with riot shields holding back the crowds, while members of the public could be seen damaging and even overturning police vehicles.

In a clip published by the Huanggang city government, which administers Huangmei, the county's Communist Party chief Ma Yanzhou could be heard speaking to the people through a loud hailer, warning them that by gathering in a large group they were increasing their chances of contracting the virus, Hong Kong-based South China Morning Post reported.

While it is unclear exactly how the clash started, police from the two sides published separate official statements online, which were quickly deleted, it said.

The incident underlines the problems China faces as it seeks a return to normalcy after months of lockdown, the Post said.

After the incident, the governments of Huangmei and Jiujiang on Friday issued a joint statement saying they had agreed to remove the barriers set up to restrict travel during the lockdown, and also to recognise each other's health screening codes to make it easier for people in good health to get to where they needed to be, the Post report said.

An article by the ruling Communist Party of China (CPC) mouthpiece, People''s Daily acknowledged the problems in getting the country back on its feet.

"In the past few days, all walks of life have called for governments to accept workers from Hubei," it said.

"However, it is undeniable that some places, intentionally or not, have set up obstacles for Hubei migrant workers to return to their posts and hold prejudices against them."

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.